ERNEST HAWK to Risk Assessment
This is a "connection" page, showing publications ERNEST HAWK has written about Risk Assessment.
Connection Strength
0.234
-
Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol. 2016 Jun 01; 2(6):770-1.
Score: 0.056
-
Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92.
Score: 0.049
-
A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):101-11.
Score: 0.027
-
Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003 Aug; 26(4):S48-57.
Score: 0.023
-
Biomarkers as surrogates for cancer development. Curr Oncol Rep. 2000 May; 2(3):242-50.
Score: 0.018
-
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
Score: 0.015
-
Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611.
Score: 0.011
-
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1.
Score: 0.008
-
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
Score: 0.008
-
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35.
Score: 0.007
-
Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004 02; 4(2):153-8.
Score: 0.006
-
Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):201-7.
Score: 0.005